

MARKET REPORT



Multiple Sclerosis: KOL Insight

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Multiple Sclerosis: KOL Insight

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

Multiple Sclerosis: KOL Insight

Introduction

Roche's/Biogen's novel ocrelizumab is set to radically alter the Multiple Sclerosis (MS) treatment paradigm. Which companies and products will lose market share as its use widens and what clinical benefits underpin KOL excitement? Could it challenge interferon therapy? Where will oral therapies such as Novartis' Gilenya (fingolimod) fit in? Where will Biogen's well regarded Tecfidera (dimethyl fumarate) find a role?

This report reveals the unique insights of 12 leading US and European KOLs - see who they are. How they view the clinical benefits of current and late-stage disease-modifying agents, safety concerns and the influence patients exert are fully explored. The report analyses 8 leading launched products and 8 significant late-stage therapies see full list.

View: US KOLS, EU KOLS, Market drugs, Pipeline drugs

"Ocrelizumab is the most exciting of all the MS drugs. This drug will take markets. This will be the most disruptive therapy of any therapy we've discussed." EU KOLv

Purchase Reasons

Answering key questions

Biotin (MD 1003; MedDay)

WHO WINS AND WHO LOSES AS THIS HIGH GROWTH SECTOR PREPARES FOR ANOTHER TREATMENT REVOLUTION? ORDER YOUR COPY NOW FOR INSTANT DOWNLOAD

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that

could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, October. You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.

Additional Details **Publisher** : FirstWord Pharma

Reference :

Number of Pages : 0

Report Format : PDF

Publisher Information :



FirstWord

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

How to Buy...Multiple Sclerosis: KOL Insight **Option 1 - Online**

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/264>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$7900** | Single User Price
- \$20500** | Global License Price
- \$25800** | Site License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.